On the other hand, a recent study demonstrated that knocking out EGRF in a mouse model of KRAS-G12D-mutant lung cancer resulted in tumor regression [45], although compensation by a non-ERBB family was seen in the later stage of the disease. This evidence concerns the gene KRAS and neoplasm.